CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 123 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2023. The put-call ratio across all filers is 1.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $253 | -31.4% | 11,600 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $369 | +67.7% | 11,600 | +28.9% | 0.00% | +100.0% |
| Q1 2023 | $220 | -22.5% | 9,000 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $284 | -99.9% | 9,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $254,000 | +10.4% | 9,000 | +3.4% | 0.00% | +100.0% |
| Q2 2022 | $230,000 | -36.3% | 8,700 | -15.5% | 0.00% | -50.0% |
| Q1 2022 | $361,000 | +8.1% | 10,300 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $334,000 | – | 10,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |